Peptide drugs QSAR study based on topomer CoMFA

Letters in Drug Design and Discovery

Volumn 14, Issue 10, 2017, Pages 1114-1121

  Tong, Jianbo ^a   Li, Lingxiao ^a   Li, Kangnan ^a   Bai, Min ^a  

^a SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Bioactive peptides; Biological activities; Model; Peptide drugs; QSAR; Tompoer CoMFA

Indexed keywords

BRADYKININ; OXYTOCIN;

ALGORITHM; ARTICLE; BITTER TASTE; CALCULATION; COMPARATIVE MOLECULAR FIELD ANALYSIS; ENERGY; IC50; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STATIC ELECTRICITY; TASTE;

EID: 85033408272     PISSN: 15701808     EISSN: 1875628X     Source Type: Journal    
DOI: 10.2174/1570180814666170504160008     Document Type: Article

References (30)

1. Xiaodan, F.; Lu, B.; Liang, Z. Marine algae-derived bioactive peptides for human nutrition and health. J. Agr. Food. Chem., 2014, 62(38), 9211-9222.
2. Hartmann, R.; Meisel, H. Food-derived peptides with biological activity: From research to food applications. Curr. Opin. Biotech., 2007, 18(2), 163-169.
3. Kensinger, R.D.; Catalone, B.J.; Krebs, F.C. Novel polysulfated galactose-derivatized dendrimers as binding antagonists of human immunodeficiency virus type 1 infection. Antimicrob. Agents. Chem., 2004, 48(5), 1614-1623.
4. Davis, M.E.; Hsieh, P. C.H.; Tomosaburo, T. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. P. Natl. Acad. Sci., 2006, 103(21), 8155-8160.
5. Yan, X.; Qiang, H.; Wang, K. Transition of cationic dipeptide nanotubes into vesicles and oligonucleotide delivery. Angew. Chem., Int., 2007, 46(14), 2431-2434.
6. Crespo, L.; Sanclimens, G.; Pons, M.; Giralt, E.; Royo, M.; Alberi-cio, F. Peptide and amide bond containing dendrimers. Chem. Rev., 2005, 105(5), 1663-1681.
7. Kagan, B.L.; Jang, H.; Capone, R. Antimicrobial properties of amyloid peptides. Mol. Pharmaceut., 2011, 9(4), 708-717.
8. Zhou, Z.; Cheng, C.; Li, Y. Structure-based design and optimization of antihypertensive peptides to obtain high inhibitory potency against both renin and angiotensin I-converting enzyme. Sar. Qsar. Environ. Res., 2015, 26(12), 1-16.
9. Dearden, J. C. The history and development of quantitative structure-activity relationships (QSARs). Int. J. Quant. Struc.-Property Rel., 2016, 1(1), 1-44.
10. Roy, K.; Kar, S.; Das, R.N. Understanding the basics of qsar for applications in pharmaceutical sciences and risk assessment. Elsevier, 2015, 1, 484.
11. Gadaleta, D. Applicability domain for qsar models: where theory meets reality. Int. J. Quant. Struc.-Property Rel., 2016, 1(1), 45-63.
12. Roy, K.; Kar, S.; Ambure P. On a simple approach for determining applicability domain of QSAR models. Chemom. Intell. Lab. Sys., 2015, 145, 22-29.
13. Cramer, R.D. Topomer CoMFA: A design methodology for rapid lead optimization. J. Med. Chem., 2003, 46(3), 374-388.
14. Jilek, R.J.; Cramer, R.D. Topomers: A validated protocol for their self-consistent generation. J. Chem. Inf. Comp. Sci., 2004, 44(4), 1221-1227.
15. Cramer, R.D.; Cruz, P.; Stahl. G. ChemInform abstract: Virtual screening for r-groups, including predicted pic50 contributions, within large structural databases, using topomer CoMFA. J. Chem. Inf. Mode., 2008, 48(11), 2180-2195.
16. Hyun-Ock, K.; Li-Chan, E.C.Y. Quantitative structure-activity relationship study of bitter peptides. J. Agr. Food. Chem., 2006, 54(26), 10102-10111.
17. Vigneaud, V.D.U.; Ressler, C.; Trippett, S. The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. J. Biol. Chem., 1953, 205(2), 949-957.
18. Adenot, M.; Menthière, C.S.D.; Chavanieu, A. Peptides quantitative structure-function relationships: an automated mutation strategy to design peptides and pseudopeptides from substitution matrices. J. Mol. Graph. Model., 1999, 17(5-6), 292-309.
19. Jonsson, J.; Eriksson, L.; Hellberg, S. Multivariate parametrization of 55 coded and non-coded amino acids. Quant. Struct. Act. Rel., 1989, 8(3), 204-209.
20. Hillebrecht, A.; Klebe, G. The Use of 3D QSAR Models for Database Screening: A Feasibility Study. J. Chem. Inf. Model., 2008, 48(2), 384-396.
21. Cramer R D.; R-group Template CoMFA Combines Benefits of “ad hoc” and Topomer Alignments Using 3D-QSAR for Lead Optimization. J. Comput. Aid. Mol. Des., 2012, 26(7), 805-19.
22. Cramer, R.D; Wendt, B. Pushing the boundaries of 3D-QSAR. J. Comput. Aid. Mol., 2007, 21(1-3), 23-32.
23. Cramer, R.D.; Clark, R.D.; Patterson, D.E. Bioisosterism as a molecular diversity descriptor: Steric fields of single "topomeric" conformers. J. Med. Chem., 1996, 39(16), 3060-3069.
24. Joshi, S.D.; More, U.A.; Aminabhavi, T.M, Two- and Three-Dimensional QSAR Studies on a Set of Antimycobacterial Pyrroles: CoMFA, Topomer CoMFA, and HQSAR. Med. Chem. Res., 2013, 23(1), 107-126.
25. Xiang, Y.; Song, J.; Zhang, Z. Topomer CoMFA and Virtual Screening Studies of Azaindole Class Renin Inhibitors. Comb. Chem. High. Throughput. Screen., 2014, 17(5), 458.
26. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity, a rapid access to atomic charges. Tetrahedron, 1980, 36(22), 3219-3228.
27. Rogers, R.D.; Rollins, A.N.; Gatrone, R.C. Comparison of the crystal structure and molecular models of N, N-diisobutyl-2-(octylphenylphosphinyl) acetamide (CMPO). J. Chem. Crystal-logr., 1995, 25(1), 43-49.
28. Powell, M.J.D. Quadratic termination properties of Davidon's new variable metric algorithm. Math. Program., 1977, 12(1), 141-147.
29. Bhonsle, J.B.; Divakaramenon, V.; Huddler, D.P. Application of 3D-QSAR for identification of descriptors defining bioactivity of antimicrobial peptides. J. Med. Chem., 2008, 50(26), 6545-6553.
30. Roy, K.; Das, R.N.; Ambure, P. Be aware of error measures. Further studies on validation of predictive QSAR models. Chemom. Intell. Lab. Sys., 2016, 152, 18-33.